company background image
MVIR

Medivir OM:MVIR B Stock Report

Last Price

kr7.63

Market Cap

kr425.2m

7D

-0.4%

1Y

-22.9%

Updated

28 Sep, 2022

Data

Company Financials +
MVIR B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MVIR B Stock Overview

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally.

Medivir AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medivir
Historical stock prices
Current Share Pricekr7.63
52 Week Highkr11.84
52 Week Lowkr7.00
Beta0.31
1 Month Change-1.29%
3 Month Change-1.29%
1 Year Change-22.93%
3 Year Change-65.63%
5 Year Change-89.02%
Change since IPO-94.26%

Recent News & Updates

Shareholder Returns

MVIR BSE BiotechsSE Market
7D-0.4%3.6%-3.3%
1Y-22.9%-33.6%-27.4%

Return vs Industry: MVIR B exceeded the Swedish Biotechs industry which returned -40% over the past year.

Return vs Market: MVIR B exceeded the Swedish Market which returned -28.2% over the past year.

Price Volatility

Is MVIR B's price volatile compared to industry and market?
MVIR B volatility
MVIR B Average Weekly Movement2.9%
Biotechs Industry Average Movement8.0%
Market Average Movement7.0%
10% most volatile stocks in SE Market11.6%
10% least volatile stocks in SE Market4.3%

Stable Share Price: MVIR B is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: MVIR B's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19879Jens Lindberghttps://www.medivir.com

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma.

Medivir AB (publ) Fundamentals Summary

How do Medivir's earnings and revenue compare to its market cap?
MVIR B fundamental statistics
Market Capkr425.18m
Earnings (TTM)-kr93.52m
Revenue (TTM)kr15.39m

27.6x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MVIR B income statement (TTM)
Revenuekr15.39m
Cost of Revenuekr83.58m
Gross Profit-kr68.18m
Other Expenseskr25.34m
Earnings-kr93.52m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 10, 2022

Earnings per share (EPS)-1.68
Gross Margin-442.92%
Net Profit Margin-607.54%
Debt/Equity Ratio0%

How did MVIR B perform over the long term?

See historical performance and comparison